|
Summary
Feb 2006, Vol. 2, No. 1, Pages 53-71
, DOI 10.2217/14796694.2.1.53
(doi:10.2217/14796694.2.1.53)
Perspective The future of photodynamic therapy in oncology Ron R Allison 1†, Vanderlei S Bagnato 2, Rosa Cuenca 3, Gordon H Downie 4 & Claudio H Sibata 51Department of Radiation Oncology, Brody School of Medicine, East Carolina University, Greenville, NC, USA & PDT Center, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA. ALLISONR@mail.ecu.edu 2Instituto de Física de São, Carlos – Universidade de São Paulo, São Carlos, SP, Brazil 3PDT Center, Brody School of Medicine, East Carolina University, Greenville, NC, USA & Department of Surgical Oncology, Brody School of Medicine, East Carolina University, Greenville, NC, USA 4PDT Center, Brody School of Medicine, East Carolina University, Greenville, NC, USA & Department of Medicine, Pulmonary and Critical Care Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA 5Department of Radiation Oncology, Brody School of Medicine, East Carolina University, Greenville, NC, USA & PDT Center, Brody School of Medicine, East Carolina University, Greenville, NC, USA † Author for correspondence The medicinal properties of light-based therapies have been appreciated for millennia. Yet, only in this century have we witnessed the birth of photodynamic therapy (PDT), which over the last few decades has emerged to prominence based on its promising results and clinical simplicity. The fundamental and distinguishing characteristics of PDT are based on the interaction of a photosensitizing agent, which, when activated by light, transfers its energy into an oxygen-dependent reaction. Clinically, this photodynamic reaction is cytotoxic and vasculotoxic. While the current age of PDT is based on oncological therapy, the future of PDT will probably show a significant expansion to non-oncological indications. This harks back to much of the original work from a century ago. Therefore, this paper will attempt to predict the future of PDT, based in part on a review of its origin.
Cited byJ. D. Vollet-Filho, P. F. C. Menezes, L. T. Moriyama, C. Grecco, C. Sibata, R. R. Allison, O. Castro e Silva, V. S. Bagnato. (2009) Possibility for a full optical determination of photodynamic therapy outcome. Journal of Applied Physics 105:10, 102038 Online publication date: 1-Feb-2009. CrossRef P.F.C. Menezes, H. Imasato, J. Ferreira, V.S. Bagnato, C.H. Sibata, J.R. Perussi. (2008) Aggregation susceptibility on phototransformation of hematoporphyrin derivatives. Laser Physics Letters 5:3, 227-235 Online publication date: 1-Apr-2008. CrossRef J. Ferreira, P.F.C. Menezes, C. Kurachi, C. Sibata, R.R. Allison, V.S. Bagnato. (2008) Photostability of different chlorine photosensitizers. Laser Physics Letters 5:2, 156-161 Online publication date: 1-Mar-2008. CrossRef Yongqing Wei, Beihua Kong, Kun Song, Xun Qu, Qiong Jin, Qifeng Yang. (2007) Involvement of Mitochondria–Caspase Pathway in Hemoporfin-mediated Cell Death. Photochemistry and Photobiology 83:6, 1319 CrossRef J. Ferreira, P.F.C. Menezes, C. Kurachi, C.H. Sibata, R.R. Allison, V.S. Bagnato. (2007) Comparative study of photodegradation of three hematoporphyrin derivative: Photofrin®, Photogem®, and Photosan®. Laser Physics Letters 4:10, 743 CrossRef Miloš Nekvasil, Marie Zadinová, Ludmila Tahotná, Markéta Žáčková, Pavla Poučková, Petr Ježek. (2007) Optimum modality for photodynamic therapy of tumors: gels containing liposomes with hydrophobic photosensitizers. Drug Development Research 68:5, 235 CrossRef
|
|
|